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A B S T R A C T
Effective treatment of glioblastoma multiforme remains a major clinical challenge, due in part to the
difﬁculty of delivering chemotherapeutics across the blood–brain barrier. Systemically administered
drugs are often poorly bioavailable in the brain, and drug efﬁcacy within the central nervous system can
be limited by peripheral toxicity. Here, we investigate the ability of systemically administered poly
(lactic-co-glycolic acid) nanoparticles (PLGA NPs) to deliver hydrophobic payloads to intracranial glioma.
Hydrophobic payload encapsulated within PLGA NPs accumulated at 10 higher levels in tumor
compared to healthy brain. Tolerability of the chemotherapeutic camptothecin (CPT) was improved by
encapsulation, enabling safe administration of up to 20mg/kg drug when encapsulated within NPs.
Immunohistochemistry staining for g-H2AFX, a marker for double-strand breaks, demonstrated higher
levels of drug activity in tumors treated with CPT-loaded NPs compared to free drug. CPT-loaded NPs
were effective in slowing the growth of intracranial GL261 tumors in immune competent C57 albino
mice, providing a signiﬁcant survival beneﬁt compared tomice receiving saline, free CPTor low dose CPT
NPs (median survival of 36.5 days compared to 28, 32, 33.5 days respectively). In sum, these data
demonstrate the feasibility of treating intracranial glioma with systemically administered nanoparticles
loaded with the otherwise ineffective chemotherapeutic CPT.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Malignant gliomas are the most common form of primary brain
tumors, afﬂicting asmany as 12,000 patients per year in the United
States (Friedman et al., 2000; Grossman and Batara, 2004).
Glioblastoma multiforme (GBM) tumors, a grade IV astrocytoma,
are distinguished by their fast growing and inﬁltrative nature. Even
after aggressive treatment, which includes tumor resection,
radiation, and chemotherapy, the median survival for patients
diagnosed with GBM is only 12–14 months (Yang et al., 2014), and
few new treatments have advanced to the clinic in the past three
decades.
One major challenge to achieving better treatment of GBM is
the difﬁculty of delivering drugs across the blood–brain barrier
(BBB), a network of endothelial cells that present both active and
passive barriers to the uptake of systemically delivered agents.
Chemotherapeutics capable of crossing the BBB are typically
poorly soluble andmay clear rapidly, and thus high systemic doses
are needed to achieve efﬁcacy. This large systemic dose can often
have severe toxic effects on peripheral tissue and organs before a
treatment beneﬁt is observed.
Thus, many drugs that could be of interest for treating
GBM cannot be delivered in doses that are both effective and
safe. For example, camptothecin (CPT), a potent DNA damaging
chemotherapeutic, is effective at killing cells in vitro, but failed in
clinical trials due to dose-limiting toxicities and, ultimately, poor
efﬁcacy. CPT is rapidly hydrolyzed at physiological pH from its
active lactone form to a 10-fold less active, more toxic carboxylate
form, which is cleared rapidly once bound to plasma proteins
(Mross et al., 2004).
Encapsulation of therapeutics such as CPT in polymeric or
liposomal nanoparticles is one strategy that could be used to
improve drug action. Drug that has been encapsulated is effectively
solubilized and protected from degradation, which prolongs
circulation time and increases bioavailability. For example, poly
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(lactic-co-glycolic acid) (PLGA) is a biocompatible and
biodegradable polymer that can be formed into nanoparticles
for encapsulation and sustained release of drug payloads. PLGA
nanoparticles are capable of encapsulating a wide range of active
agents for sustained release in biological environments, including
CPT (Dawidczyk et al., 2014; Dinarvand et al., 2011; Tosi et al.,
2013). CPT potency is improved by encapsulation and sustained
release when infused directly into tumors (Cirpanli et al., 2010;
Sawyer et al., 2011). However, the question of whether CPT-loaded
PLGA nanoparticles are capable of treating tumors within the brain
when administered intravenously remains unanswered.
The goal of this work was to evaluate the ability of systemically
administered CPT-loaded PLGA NPs to treat intracranial GBM in
mice. GL261 is a syngeneic mouse glioma cell line that mimics
many of the proliferative, invasive, and diffuse characteristics of
human GBM (Jacobs et al., 2011; Newcomb and Zagzag, 2009).
The use of luciferase expressing GL261 cells (GL261-luc2) allows
us to track tumor growth in vivo with bioluminescence and,
therefore, NP efﬁcacy in immune-competent C57BL/6 albino mice.
Nanoparticles were administered to mice bearing orthotopic
GL261-luc2 tumors to evaluate speciﬁc payload delivery to tumor,
peri-tumor, and healthy brain tissue. Efﬁcacy of free CPT versus
CPT encapsulated at two doses was determined by tumor growth
and survival to test the hypothesis that encapsulation of
chemotherapeutic in a nanoparticle could improve systemic
therapy of orthotopic GBM.
2. Materials and methods
Camptothecin (CPT),1,10-dioctadecyl-3,3,30,30-tetramethylindo-
tricarbocyanine iodide (DiR), dichloromethane (DCM), methanol,
dimethyl sulfoxide (DMSO), 10% neutral buffered formalin,
E-TOXA-Clean and polyvinyl alcohol (PVA) were all purchased
from Sigma–Aldrich (St. Louis, MO, USA). Ester terminated
poly (lactic-co-glycolic acid) (PLGA) (50:50; inherent viscosity =
0.59 dL/g) was obtained from Lactel (Birmingham, AL, USA). All
water used in nanoparticle fabrication was endotoxin free
(<0.0050EU/ml) purchased from G-biosciences (St. Louis, MO,
USA). Dulbecco’s modiﬁed Eagle medium (DMEM), fetal bovine
serum (FBS), 0.25% trypsin-EDTA and geneticin selective antibiotic
(G-418) were purchased fromGibco Invitrogen (Carlsbad, CA, USA).
Greiner T25 tissue culture ﬂasks with ﬁlter cap and Costar 96 well
assay plates (black, ﬂat-bottom, non-treated polystyrene) were
purchased from VWR International (Radnor, PA, USA). Beetle
luciferin, potassium salt was purchased from Promega (Madison,
WI, UAS). GL261-luc2 cells were a generous gift from Dr. Adrienne
Scheck (Barrow Neurological Institute, Phoenix, AZ, USA).
2.1. Cell culture
GL261-luc2 expressing cells were maintained at 37 C and 5%
CO2 on T25 tissue cultures ﬂasks in DMEM supplemented with
glucose, L-glutamine, 10% FBS and G-418 antibiotic. Cells were
detached with 0.25% trypsin-EDTA and counted using a cellometer
mini (Nexcelom Bioscience, Lawrence, MA, USA) to obtain a ﬁnal
concentration of 50,000 cells/2ml for tumor inductions.
2.2. Nanoparticle fabrication
Nanoparticles were fabricated in endotoxin-free conditions. All
glassware and centrifuge tubes were soaked overnight in a 1% w/v
E-TOXA-Clean solution and glassware was baked at 250 C for
30min. Nanoparticles were produced by single emulsion-solvent
evaporation (McCall and Sirianni, 2013) with slight modiﬁcation.
Brieﬂy, 100mg of PLGA and either 625mg DiR or 8mg CPT was
dissolved in 1ml of a 4:1 DCM: methanol mixture. The dissolved
PLGA was added dropwise into 2ml of 5% (w/v) PVA under
vortexing and probe sonicated (Fisher Scientiﬁc Model 705 Sonic
Dismembrator, Waltham, MA, USA) on ice in 3, 10-s bursts at 40%
amplitude. The resulting emulsionwas added to 50ml of 0.3% PVA,
and this solution was stirred for 3h to evaporate solvent. Nano-
particles were collected by centrifugation for 20min at 20,000 RCF
andthe resultingnanoparticlepelletwaswashedthreetimeswithDI
water. The ﬁnal nanoparticle pellet was resuspended in 1ml
endotoxin freewatercontaining25mgTrehalose, frozen, lyophilized
for 48h, and stored at80 C. Blank nanoparticlesweremadeby the
same method as above without the addition of CPT or DiR.
2.3. Particle characterization
2.3.1. Sizing and morphology
To visualize surface morphology, lyophilized nanoparticles
were mounted on double-sided carbon tape and sputter coated
with gold for 30 s at 40mA. Samples were imaged on a SEM-
XL30 Environmental FEG at 10 kV. Nanoparticle diameters were
measured with ImageJ (v. 1.48, NIH) for a minimum of 200
nanoparticles taken from 5 images. The hydrodynamic diameter
and zeta potential of nanoparticles were determined at a
concentration of 1mg/ml in water by dynamic light scattering
(DLS) using a Delsa Nano C (Beckman Coulter, Pasadena, CA, USA).
2.3.2. Drug loading
Loading of CPT and DiR were determined by ﬂuorescence.
Nanoparticles were dissolved in DMSO to a concentration of
5mg/ml. The nanoparticle solution (40ml) and DMSO (10ml) were
pipetted into a black ﬂat bottom 96 well plate and read on a
ﬂuorescent plate reader at the appropriate wavelengths (EX/EM
370/428nm or 750/780nm, for CPT or DiR respectively). Three
samples were read with technical triplicates averaged. Control
curves were constructed by dissolving blank nanoparticles as
described above and spiking with known amounts of drug or dye.
2.3.3. Controlled release
The method for measuring release of CPT from nanoparticles
was adapted from a method described previously (Deng et al.,
2014). Nanoparticles (150mg) with or without CPT were
suspended in 2ml of 1 PBS and incubated at 37 C on a shaker.
At regular intervals (0.5, 2, 4, 6, 24 and 48h) sampleswere removed
and centrifuged for 10min at 20,000 RCF. The nanoparticle pellet
was discarded and 970ml of the supernatant was removed and
added to 30ml of quantiﬁcation ﬂuid (DMSO: 1N HCL: 10% SDS).
Control curves were constructed by spiking blank particle samples
with known quantities of CPT for ﬂuorescent readout by the
method described above. Three samples were measured for each
time point.
2.4. In vivo studies
Nanoparticle brain distribution and tumor treatment
efﬁcacy were examined in vivo in a total of 64 C57BL/6 albino
mice (Harlan Laboratories, Indianapolis, IN, USA). All procedures
and animal care practices were performed in accordance with
the Barrow Neurological Institute’s Institutional Animal Care and
Use Committee.
2.4.1. Tumor inductions
Tumor induction protocol followed the methods established by
(Abdelwahab et al., 2011) with some modiﬁcations. Mice were
anesthetized with an intraperitoneal injection of ketamine
(100mg/kg) and xylazine (10mg/kg) and mounted on a small
animal stereotaxic instrument (Model 900, Kopf Instruments,
Tujunga, CA, USA). Animal temperature was maintained using a
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circulating water heating pad placed beneath the frame. A sterile
surgical ﬁeld was obtained by three alternating passes of betadine
solution and 70% isopropanol over the surgical site. An incisionwas
made down the midline of the scalp to expose the skull and a burr
hole was drilled to target the striatum (2mm lateral and 0.1mm
posterior from bregma). A Hamilton syringe ﬁlled with 2ml of the
cell suspension (50 k cells) was lowered to a depth of 3mm and
allowed to equilibrate with tissue for 1min. The syringe was then
withdrawn to a depth of 2.6mm and the cells were infused over
2min. The syringewas left in place for 1min before it was removed
to reduce back ﬂow. The incision was closed using staples and a
triple antibiotic ointment was applied to the scalp before placing
the animal in a clean cage over a heating pad to recover. All animals
received a single subcutaneous (SQ) injection of buprenorphine
(0.1mg/kg). Ibuprofen was provided in drinking water for 1 week
post-op to control pain.
2.4.2. Tumor growth
Tumor growth was monitored every 3–4 days after tumor
induction using the Xenogen IVIS Spectrum in vivo imaging system
(Caliper Life Sciences, Hopkinton, MA, USA). Mice received a SQ
injection of 150mg Luciferin/kg andwere imaged under anesthesia
(2% isoﬂurane) at 25min post injection. Regions of interest (ROIs)
were drawn by hand to measure total ﬂux (photons/s) using the
IVIS Living Image software.
2.4.3. Tumor localization of particles
25 tumor bearing C57BL/6 albino mice were used to measure
accumulation of payload in tumor, peri-tumor and healthy brain
tissue. Mice were imaged on the IVIS system one day prior to
injection to determine tumor size. On days 4, 8, 12, 16 or 20,
mice (n=5/day) were injected with DiR-loaded nanoparticles
(180mg/kg) in 0.2mL by tail vein. 2 h post-injection, a blood
sample was collected by cardiac puncture before mice were
sacriﬁced and the brain removed, rinsed, and stored at 80 C.
Frozen brainswere sliced into 2mm thick sections and imaged on a
LI-COR Odyssey CLx (LI-COR Biosciences, Lincoln, NE, USA). After
slices were imaged, 2mm diameter punches were taken from
tumor, peri-tumor and healthy (contralateral) striatal regions. The
tissue punches were probe sonicated in 2.5% w/v water for 2, 10 s
bursts (40% amplitude). Tissue homogenates (50ml) were mixed
with DMSO (10ml) in triplicate in a 96 well plate for ﬂuorescent
readout (EX/EM 750/780nm). Control curves were constructed by
processing punches from tumor bearing mice that did not receive
nanoparticles (n =8mice) and spikingwith known amounts of DiR.
2.4.4. Tumor treatment efﬁcacy
The antitumor efﬁcacy of CPT-loaded PLGA nanoparticles
was tested in 31 C57BL/6 albino mice bearing orthotopic
GL261-luc2 tumors. Animals were randomized into four treatment
groups: saline, free CPT (10mg/kg CPT), nanoparticle-encapsulated
CPT at a low dose (10mg/kg CPT) (NP-10), and nanoparticle-
encapsulated CPT at a high dose (20mg/kg CPT) (NP-20). Free CPT
was prepared for injection by dissolving CPT (50mg/ml) in 1M
NaOH and titrating the pH to 7 with PBS for a ﬁnal solution of
1mg/ml CPT. Nanoparticles were prepared for injection by
resuspension in sterile saline, and sonicated for 10min to ensure
no aggregates remained (Fisher ScientiﬁcModel FS30). Treatments
were administered intravenously (IV) by tail vein injection on days
8, 15 and 22 after tumor induction. Treatment efﬁcacy was
determined by tumor growth measured by IVIS, as described in
Section 2.4.2, every 3–4 days following tumor induction and
differences in mean survival time. Mice were monitored daily and
euthanized upon >15% weight loss or signs of neurological
symptoms.
2.4.5. Camptothecin activity
CPT activity in vivowas evaluated using immunohistochemistry
(IHC). C57BL/6 albino mice bearing orthotopic GL261-luc2 tumors
received an injection of saline, free CPT or NP-20 and were
euthanized 2h after treatment by cardiac perfusion with
heparinized saline followed by 10% buffered formalin. Animal
brains from each treatment group were harvested for tissue
analysis. Formalin ﬁxed brains were sliced into thick sections and
embedded in parafﬁn. H&E staining and IHC staining were
performed as described previously (Dhruv et al., 2013). Brieﬂy,
5mM thick sections from the tissue blocks were baked at 65 C for
1h, deparafﬁnized in three xylene washes, dehydrated in series
graded ethanol, and rehydrated inwater. Each slide was blocked in
blocking buffer (3% goat serum, 1% BSA in PBS) and antigens
were retrieved using a sodium citrate buffer (pH 6.5) for
20min (BondMax Autostainer; Vision Biosystems, Norwell, MA).
[(Fig._1)TD$FIG]
Fig.1. (A) Representative SEM image of CPT-loaded PLGA nanoparticles. (B) CPTwas released from nanoparticles into buffer, with80% of total drug released after 6h. Points
and error bars represent themean SD, with 3 samplesmeasured for each time point. (C) CPT- and DiR-loaded nanoparticles had similar diameters, as measured by SEM and
DLS, and similar surface charges. (Scale bar = 500mm).
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IHC staining for gH2A.X (#9718, Cell Signaling Technology) and
CD31 (ab28364, Abcam) was performed on serial sections from
tissue blocks. Slides were incubated with primary antibodies,
rinsed, and incubated with a HRP-conjugated secondary antibody
for 30min followed by a DAB substrate. Lastly, sections were
counterstained with hematoxylin and coverslipped.
2.5. Statistics
All data analysis was performed in GraphPad Prism 5 software.
Brain distribution datawere evaluated bya 2-way ANOVA followed
by Bonferroni post-test. Tumor growth curves were evaluated by
ﬁtting the growth data with a ﬁrst-order exponential and
comparing tumor doubling times using an ANOVA followed by
Tukey’s multiple comparison test. Survival differences were
evaluated from the Kaplan–Meier plot with the Mantel–Cox test.
Differences were considered statistically signiﬁcant for an alpha
level of 0.05.
3. Results
3.1. Nanoparticle characterization
SEM analysis conﬁrmed that nanoparticles possessed a
spherical shape with smooth surface morphology (Fig. 1A,
Supplementary Fig. 1). Nanoparticles sizes were relatively
monodisperse (Fig. 1(A and C)) with a mean particle diameter of
12331 and 11937nm for CPT and DiR nanoparticles,
respectively, as measured by SEM. DLS measurements yielded
hydrodynamic diameters of 20632 and 204 41nm respectively
and zeta potentials of 21.1 and 23.7mV for CPT and DiR loaded
nanoparticles, respectively (Fig. 1C). Hydrophobic agents were
effectively encapsulated in the NPs with drug loading efﬁciency of
9.6% for CPTand 0.5% for DiR. The CPT release proﬁle of the particles
was determined in vitro in PBS at 37 C (Fig. 1B). Drug was initially
released from nanoparticles in a burst of 80% over 6h, and
complete CPT release was observed within 24h.
Supplementry material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.ijpharm.2015.01.002.
3.2. In vivo studies
3.2.1. Tumor localization
NPs loaded with DiR, a hydrophobic, near infrared dye shown
to release less than 5% in 24h and commonly used to track NPs
(Lu et al., 2014; Yao et al., 2014), were administered IV to evaluate
the ability of NPs to deliver hydrophobic payload to intracranial
GL261-luc2 tumors. Biopsy punches were taken from the tumor
core, peri-tumor region below the tumor, and contralateral
(healthy) hemisphere (Fig. 2A). Nanoparticle payload accumulated
in the tumor core at signiﬁcantly higher concentrations compared
to both healthy and peri-tumor brain regions (p<0.05) at day 12,
16 and 20 (Fig. 2B). Payload delivery was positively correlated to
tumor size for both tumor core and peri-tumor regions
(p =0.0002 and 0.048, respectively) (Fig. 2C).
3.2.2. Tumor treatment efﬁcacy
The tolerability and efﬁcacy of CPT delivered in nanoparticle-
encapsulated versus free form were evaluated in C57BL/6 albino
mice bearing intracranial GL261-luc2 tumors. Subjects received
weekly injections of saline, free CPT, NP-10, or NP-20 for 3 cycles.
Subjects that received nanoparticle encapsulated CPT at both low
and high dose experienced similar weight loss following treatment
when compared to free CPT (Fig. 3A, shown with error bars in
Supplementary Fig. 2). Tumor growth in saline-treated subjects
was exponential, and no signiﬁcant differences in tumor size were
observed for mice treated with free CPT or NP-10 (Fig. 3B).
However, tumor growth was signiﬁcantly slowed by treatment
with NP-20. Additionally, NP-20 provided a signiﬁcant survival
beneﬁt over the other treatment groups with a median survival of
36.5 days compared to 28, 32 and 33.5 days for saline, free CPT and
NP-10 respectively (Fig. 3C). In a separate series of experiments, we
established that blank nanoparticles did not alter survival when
compared to saline treated controls (Supplementary Fig. 3).
[(Fig._2)TD$FIG]
Fig. 2. (A) DiR distribution (green) in a tumor bearing mouse brain captured on the
LI-COROddyssey. Regions marked indicate example tissue punch locations used for
tumor (1), peri-tumor (2) and healthy brain (3). (B) DiR accumulation was
signiﬁcantly higher in the tumor compared to peri-tumor or healthy brain regions,
12, 16 and 20 days post tumor implantation (p= 0.01) Bars indicate mean SD
(n =5mice/day). (C) The amount of DiR/g tissue, quantiﬁed by ﬂuorescence for each
region, positively correlated with tumor size for both tumor core and peri-tumor
regions (p =0.002 and 0.048, respectively).
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Supplementry material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.ijpharm.2015.01.002.
3.2.3. Camptothecin activity
CPT bioactivity was examined by gH2A.X staining in intracranial
tumors of animals treated with saline, free CPT, and nanoparticle
encapsulated CPT (Fig. 4). Tumor sections taken from NP-20 treated
mice showed an increase in staining intensity ofgH2A.X compared to
free CPT, with an average score of 3.0 as compared to 2.0, respectively
(blindedscoringperformedbyboardcertiﬁedpathologist). Thesedata
support the hypothesis that encapsulation of CPT in nanoparticles
allows for the delivery of greater amounts of CPT without adverse
effects (Fig. 4). To rule out the possibility that higher delivery of
nanoparticle encapsulated CPTwas due to higher vascularity of those
particular subjects, we also examined CD31 staining intensity across
different treatment groups (Fox et al., 1993). Each treatment group
showed similar CD31 staining intensity.
4. Discussion
This study presents the use of CPT-loaded PLGA NPs for the
systemic treatment of an orthotopic murine glioma. We achieved
a loading of CPT in our nanoparticles of 10% by weight; this
value is higher than our theoretical loading of 8%, indicating that
more PLGA was lost than CPT during the nanoparticle fabrication
process. Loss of PLGA during nanoparticle fabrication has been
reported previously (Sawyer et al., 2011), and our loading is
consistent with the 5–25% loading reported by other groups
encapsulating CPT in PLGA (Deng et al., 2014; McCarron et al.,
2008). The average hydrated nanoparticle diameter measured by
DLS (200nm) was larger than the diameter measured by SEM
(120nm), which is expected, given that NPs will become
hydrated in the aqueous environment required for DLS and that a
fraction of nanoparticles will experience aggregation after
resuspension. The zeta potential of our nanoparticles was
approximately 21mV, which is more negative than the
purposed optimal range of 10 to +10mV required to minimize
nonspeciﬁc nanoparticle interactions and MPS cell clearance
(Davis, 2009). NPs displayed CPT release kinetics typically
observed for PLGA nanoparticles, with an initial, rapid burst
release followed by a period of slowed release and the majority of
drug being released within several days. Drug was therefore
effectively encapsulated for subsequent release in physiological
environments.
One advantage of using PLGA nanoparticles as drug delivery
vehicles is that encapsulation of hydrophobic agents can improve
their solubility and reduce toxicity. Toxicity remains a problem for
CPT, which has a literature reported maximum tolerated dose
(MTD) of 8–10mg/kg (Han and Davis, 2013). In our hands,
injection of free CPT at a dose of 16mg/kg caused almost instant
death (5–10 s), presumably due to its poor solubility. However,
CPT was well-tolerated when encapsulated in PLGA NPs; no signs
of acute drug toxicity were observed for doses of up to 30mg/kg.
We observed an MTD for PLGA-CPT NPs of 20mg/kg CPT, with
higher doses resulting in weight loss after treatment (data not
shown). This increase in CPT tolerability could be due to a
combination of increased solubility and reduction of peak dose
due to prolonged release of CPT from the particles. The extended
release proﬁle seen could also increase tolerability by allowing
particles to deliver CPT to the tumor or be cleared before a
majority of the CPT is released, thereby reducing CPT exposure to
healthy cells.
[(Fig._3)TD$FIG]
Fig. 3. (A) Mice receiving CPT either freely or in a NP showed similar weight ﬂuctuations over the course of treatments. Saline treated mice weight remained steady until the
tumor burden became too great. (B) Tumor burdenmonitored by IVIS showedNP-20 signiﬁcantly slowed tumor growth (p= 0.01) and provided a signiﬁcant survival beneﬁt (C
and D) compared to all other treatments. Error bars indicate SD.
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The difﬁculty of delivering drugs across the BBB makes the use
of an intracranial tumor model critical for evaluating nanoparticle
drug delivery; however, the most common GBM models (i.e. U87,
U118, 9L) grow as bulky tumors, with well-deﬁned borders and a
highly disrupted BBB (Jacobs et al., 2011; Newcomb and Zagzag,
2009). The GL261 tumor model was chosen for this work for
several reasons. First, human GBM is characterized by diffuse and
highly inﬁltrative growth, and it has been shown that
GL261 tumors better recapitulate these characteristics with tumor
cells invading into surrounding brain parenchymawhere the BBB is
still intact (Seligman et al., 1939; Szatmári et al., 2006).
Additionally, GL261 cells share key genomic features with human
GBM, including activated K-ras (mutant) and mutant p53, along
with increased activation of the PI3K/Akt pathway (Jacobs et al.,
2011; Oh et al., 2014). Here we utilized a luc2 transfected
GL261 model, which has been shown to have the same growth
characteristics in vivo as the parent cell line, while enabling
noninvasive tracking of tumor growth over time (Abdelwahab
et al., 2011; Clark et al., 2014). In future work, this model could be
used to evaluate the delivery of molecularly targeted drugs that
would not otherwise cross the BBB.
It is well-established that nanoparticles can extravasate from
peripheral circulation through leaky tumor vasculature into tumor
core, a phenomenon termed the enhanced permeation and retention
(EPR) effect; however, the optimal nanoparticle size for achieving the
greatestEPReffectwilldependonanumberof factors includingtumor
type, location, and size of tumor. EPR data has been reported for
nanoparticles ranging from 20–1000nm in various tumor models
(Acharya and Sahoo, 2011; Fang et al., 2011; Greish, 2010; Prabhakar
et al., 2013). Previously, 10nm DSPE-PEG micelles have been shown
topassivelyaccumulate in intracranialGL261 tumors;however, toour
knowledge, the nanoparticle size requirement for EPR-mediated
deliverytointracranialGL261tumorshasnotbeenevaluated.Thus,we
were interested to study how nanoparticle payload was delivered
selectively to tumor core versus periphery during tumor progression.
Biopsy punches taken from the brains of tumor bearing mice
administered PLGA-DiR NPs demonstrated that NPs preferentially
accumulate in the tumor core, and this preferential delivery increased
asa functionof tumorsizeandwith timepost-tumor induction. These
data suggest that effective delivery of hydrophobic payloads can be
achieved even in late stages of growth in this intracranial model.
The growth of intracranial GL261-luc2 tumors was unaffected
by treatment with free drug or with encapsulated drug at the MTD
for free drug of 10mg/kg. However, CPT-loaded PLGA nanoparticles
delivered systemically at a dose of 20mg/kg CPT slowed tumor
growth and produced a signiﬁcant increase in survival compared to
all other treatments. CPT is a potent DNA damaging therapy and
acts on cells by inhibiting enzyme DNA topoisomerase I, which
leads to generation of DNA double strand breaks (DSB), leading to
apoptosis. DSB activates the DNA damage response (DDR) and
produces accumulation of phosphorylated histone H2A.X (gH2A.
X), a hallmark of DDR (Furuta et al., 2003). IHC analysis of gH2A.X
validates that the slowed tumor growth and signiﬁcant increase in
survival of animals treated with NP-20 was due to the enhanced
tolerability of nanoparticle encapsulated CPT, which enabled a
higher total dose to be delivered.
[(Fig._4)TD$FIG]
Fig. 4. Left panel showsH&E staining of the tumor cells in saline, free CPTand nanoparticle encapsulated CPT (20mg/Kg) treated animals. Center panel showsgH2A.X staining
on the serial section, and demonstrates very high gH2A.X staining for animals treated with nanoparticle encapsulated CPT (20mg/Kg) (IHC score= 3) as compared to saline
(IHC score=1–2) and free CPT (IHC score= 2) treated animals. Right panel shows the CD31 staining on the serial section, and demonstrates similar staining intensity in all the
treatment group. Positive staining in each section is indicated by black arrow. All the images are taken at 20magniﬁcation (scale bar in top left panel = 100mm). (n =3mice/
treatment).
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PLGA is both biocompatible and biodegradable, and has been
used extensively for improving the action of chemotherapeutics
(Dawidczyk et al., 2014; Dinarvand et al., 2011; Gu et al., 2013; Guo
et al., 2013; Tosi et al., 2013), including in humans. For example,
PLA-PEG nanoparticles encapsulating the chemotherapeutic drug
doxorubicin are the subject of a phase II clinical trial in prostate
cancer and non-small cell lung carcinoma (Hrkach et al., 2012).
Other groups have encapsulated CPT within PLGA nanoparticles,
and these formulations were effective when delivered directly to
intracranial tumors, either by convection enhance delivery or from
inside a hydrogel implant (Cirpanli et al., 2010; Sawyer et al., 2011).
The data presented here conﬁrm that encapsulation of CPT can
improve its activity. To our knowledge, this study is the ﬁrst to
report effective therapy of an intracranial tumor by systemic
administration of CPT-loaded PLGA nanoparticles. Surface
modiﬁcation of nanoparticles – for example, attachment of poly
(ethylene glycol) to improve circulation time, or ligands designed
to facilitate transport of nanoparticles across the BBB could further
improve payload delivery to the CNS (McCall et al., 2014).
Enhancing delivery across an intact BBB to provide pan-CNS
delivery of chemotherapies will improve drug access to invading
cancer cells to improve tumor therapy.
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